ID   LN-308
AC   CVCL_0394
SY   LN 308; LN308; LNZ-308; LNZ 308; LNZ308; LN-Z308
DR   BTO; BTO:0004457
DR   MCCL; MCC:0000289
DR   BioGRID_ORCS_Cell_line; 406
DR   BioSample; SAMN10988416
DR   cancercelllines; CVCL_0394
DR   Cell_Model_Passport; SIDM00682
DR   Cosmic; 849863
DR   Cosmic; 2367499
DR   Cosmic; 2516023
DR   DepMap; ACH-000760
DR   IARC_TP53; 22502
DR   PharmacoDB; LNZ308_852_2019
DR   PRIDE; PXD008984
DR   Wikidata; Q54902775
RX   DOI=10.1007/0-306-46861-1_11;
RX   PubMed=2990147;
RX   PubMed=7693337;
RX   PubMed=9842975;
RX   PubMed=10416987;
RX   PubMed=11351043;
RX   PubMed=14614447;
RX   PubMed=14655754;
RX   PubMed=17595512;
RX   PubMed=20504876;
RX   PubMed=20593219;
RX   PubMed=22570425;
RX   PubMed=25984343;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 59 hours (PubMed=9842975); 30 hours (PubMed=25984343).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=10416987; PubMed=14614447).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
CC   Genome ancestry: African=0.02%; Native American=0.47%; East Asian, North=2.42%; East Asian, South=0%; South Asian=0%; European, North=44.33%; European, South=52.76% (PubMed=30894373).
CC   Derived from site: In situ; Brain, right parieto-occipital lobe.
ST   Source(s): PubMed=22570425
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,13
ST   D16S539: 9,12
ST   D18S51: 13,19
ST   D21S11: 31,31.2
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 10,12
ST   D8S1179: 8,13
ST   FGA: 18,20
ST   Penta D: 9,11
ST   Penta E: 7,10
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 15,17
DI   NCIt; C60781; Astrocytoma
DI   ORDO; Orphanet_94; Astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 26
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=2990147; DOI=10.1007/BF00688585;
RA   Studer A., de Tribolet N., Diserens A.-C., Gaide A.-C.,
RA   Matthieu J.-M., Carrel S., Stavrou D.;
RT   "Characterization of four human malignant glioma cell lines.";
RL   Acta Neuropathol. 66:208-217(1985).
//
RX   PubMed=7693337;
RA   Li H., Hamou M.-F., de Tribolet N., Jaufeerally R., Hofmann M.,
RA   Diserens A.-C., Van Meir E.G.;
RT   "Variant CD44 adhesion molecules are expressed in human brain
RT   metastases but not in glioblastomas.";
RL   Cancer Res. 53:5345-5349(1993).
//
RX   PubMed=9842975; DOI=10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-z;
RA   Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N.,
RA   Krajewski S., Reed J.C., von Deimling A., Dichgans J.;
RT   "Predicting chemoresistance in human malignant glioma cells: the role
RT   of molecular genetic analyses.";
RL   Int. J. Cancer 79:640-644(1998).
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=11351043; DOI=10.1038/labinvest.3780280;
RA   Hui A.B.-Y., Lo K.-W., Yin X.-L., Poon W.-S., Ng H.-K.;
RT   "Detection of multiple gene amplifications in glioblastoma multiforme
RT   using array-based comparative genomic hybridization.";
RL   Lab. Invest. 81:717-723(2001).
//
RX   PubMed=14614447; DOI=10.1038/sj.onc.1207198;
RA   Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.;
RT   "CP-31398, a novel p53-stabilizing agent, induces p53-dependent and
RT   p53-independent glioma cell death.";
RL   Oncogene 22:8233-8245(2003).
//
RX   PubMed=14655754; DOI=10.1111/j.1750-3639.2003.tb00479.x;
RA   Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W.;
RT   "P-glycoprotein and multidrug resistance-associated protein mediate
RT   specific patterns of multidrug resistance in malignant glioma cell
RT   lines, but not in primary glioma cells.";
RL   Brain Pathol. 13:482-494(2003).
//
RX   PubMed=17595512; DOI=10.1159/000104150;
RA   Rieger J., Frank B., Weller M., Wick W.;
RT   "Mechanisms of resistance of human glioma cells to Apo2
RT   ligand/TNF-related apoptosis-inducing ligand.";
RL   Cell. Physiol. Biochem. 20:23-34(2007).
//
RX   PubMed=20504876; DOI=10.1093/neuonc/noq051;
RA   Berger B., Capper D., Lemke D., Pfenning P.-N., Platten M., Weller M.,
RA   von Deimling A., Wick W., Weiler M.;
RT   "Defective p53 antiangiogenic signaling in glioblastoma.";
RL   Neuro-oncol. 12:894-907(2010).
//
RX   PubMed=20593219; DOI=10.1007/s11060-010-0283-9;
RA   Blough M.D., Beauchamp D.C., Westgate M.R., Kelly J.J.P.,
RA   Cairncross J.G.;
RT   "Effect of aberrant p53 function on temozolomide sensitivity of glioma
RT   cell lines and brain tumor initiating cells from glioblastoma.";
RL   J. Neurooncol. 102:1-7(2011).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//